

Vancocin (vancomycin) Capsules

Policy Number: C5325-C

CRITERIA EFFECTIVE DATES:

ORIGINAL EFFECTIVE DATE	LAST REVIEWED DATE	NEXT REVIEW DATE
06/2013	12/2018	12/2019
J CODE	TYPE OF CRITERIA	LAST P&T APPROVAL
NA	RxPA	Q2

PRODUCTS AFFECTED: Vancocin (vancomycin) Capsules**DRUG CLASS:** Glycopeptides**ROUTE OF ADMINISTRATION:** Oral**PLACE OF SERVICE:**

Retail Pharmacy

AVAILABLE DOSAGE FORMS: vancomycin 125mg cap, 250mg cap, Vancocin 125mg cap, 250mg cap**FDA-APPROVED USES:** indicated for the treatment of C. difficile-associated diarrhea. Vancocin capsules are also used for the treatment of enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains).**COMPENDIAL APPROVED OFF-LABELED USES:** None

COVERAGE CRITERIA: INITIAL AUTHORIZATION**DIAGNOSIS:** C. difficile-associated diarrhea.**REQUIRED MEDICAL INFORMATION:****A. PSEUDOMEMBRANOUS COLITIS DUE TO C. DIFFICILE:**

1. The patient has the diagnosis of *Clostridium difficile*-associated diarrhea (CDAD) confirmed by a positive stool assay
AND
2. The patient has experienced inadequate treatment response to PREFERRED formulary product (First- Vanc or Firvanq)

DURATION OF APPROVAL: Initial authorization: up to 14 days, Continuation of therapy: NA**QUANTITY:** 125 mg PO 4 times daily for 10 days (for fulminant cases, 500 mg PO or via nasogastric tube 4 times daily)**PRESCRIBER REQUIREMENTS:** None**AGE RESTRICTIONS:** None**GENDER:**

Male and female

CONTINUATION OF THERAPY: NA

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION: All other uses of Vancocin (vancomycin) Capsules are considered experimental/investigational and therefore, will follow Molina's Off-Label policy

OTHER SPECIAL CONSIDERATIONS: None

BACKGROUND: None

APPENDIX: None

REFERENCES:

1. Vancocin Capsules [package insert]. Baudette, MN: Ani Pharmaceuticals Inc.; August 2014.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed December 2016.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription].
4. Cohen S, Gerdin D, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infection Control and Hospital Epidemiology* 2010;31:431-455.
5. Zar F, Bakkanagari S, Moorthi S, Davis M. A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. *Clinical Infectious Diseases* 2007;45:302-307.
6. Centers for Disease Control. Clostridium difficile Infection. Available at http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_infect.html.
7. Gould C, McDonald C. Bench-to-bedside review: Clostridium difficile colitis. *Critical Care* 2008;12:203-211.
8. Safety and Efficacy of Fidaxomicin in the Treatment of Clostridium difficile-associated Diarrhea. Available at http://www.medscape.com/viewarticle/774585_1-1